April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Grants Fast Track and Rare Pediatric Disease Designations for WU-CART-007 in T-ALL/LBL
July 20th 2022The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Read More
FDA Approval Application for U2 Regimen in CLL and SLL Voluntarily Withdrawn
April 18th 2022With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.
Read More
Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALL
January 7th 2022Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Watch